Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep I have seen four different reports since Monday.
I have actually been posting about Scancell on AIM share chat for a couple of months, just getting people to take a look at the potential. Funny enough Zak Mirs picks feature heavily on that link and I note he has given us a mention too.
Thanks to a few of you guys for supporting that, if someone fancies keeping that updated please do, not a great time for me at the moment.
Thanks all, as you can tell, I've just been doing a 24 hour time limited search.
I suppose we should be glad that 2 news outlets picked it up, even if one misreported part of it yesterday.
Lochinvar, on the Scancell LSE Homepage, on the top line second from left, you will see SCLP share news. You will find Alliance News updates there.
Thanks Lochinvar, Alliance News tend to comment after an RNS is issued, hence Monday. It is just the body of the RNS and how the share has traded since being released that day.
Note that the...
https://www.lse.co.uk/news/scancell-teams-to-evaluate-its-antibody-platform-for-cancer-treatment-vsuvksfeufwxvrk.html
Noe that the research agreement was prefaced earlier in the article as non-exclusive:
"Under the terms of the collaboration & research agreement, the unnamed Scancell's partner will conduct preclinical studies to evaluate Scancell's anti-tumour-associated glycans monoclonal antibodies for the treatment of cancer."
I just spotted this one which seems to be culled from elsewhere.
Scancell did not RNS their first IND submission.
Correct
There is every chance scancell and Ichor have re-applied at the FDA for that US trial...my understanding from Cliff was we would not be told that ... we will just (hopefully) wake up to an RNS saying US trial back on... and at this point, it is looking to me that the plan if there is one is actually to mainly run it in the US as was the original plan... If the FDA play along if not looks like SCIB1 combo will be something of a nothing trial...Think proactive not for first times have some facts mixed up in their reporting of scancell.... With Avidimab we know the first partner is running to a one year plan we also know that could change as Cliff said as others come in showing an interest the pressure on them to finalise a commercial deal increases as soon as they are seeing things in their lab research that they are liking .It would be nice to think SCIB2 trial is starting in a couple of weeks time though lol
It is not in Bermudas link that just concentrates on the third platform
https://www.pbiforum.net/mag/featured/third-agreement-signed-for-scancells-antibody-platform/
https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-exploring-new-frontiers-in-cancer-research-220600.html
This is the proactive page. SCIB1 timetable way out of date, but the Modi1 timetable still feasible hopefully.
Ahh ok I'll have to have a look
Hi crumbs, yeah the last couple of days Bermuda posted in a link in Scancell Twitter and I think it was Lochinvar Lass who posted another yesterday, pretty sure in one of those or both they gave some mention to waiting on Approval in the U.S.A
I must have missed something... have you a link to the articles?
Well that is our big hope, perhaps next week, to get some positive news re trials. The third platform potentially is speaking for itself ATM and it is my real hope as alluded too in those two articles yesterday that we can resubmit the IND ASAP.
According to the proactive slide posted yesterday, the dosing level data is to be released early next year. This assumes that the trial starts q1 this year.
Let's see if we have an update on this in the interims.
But looks like Lindy will be presenting in Basel in Nov at the festival of biologics...
https://terrapinn-cdn.com/conference/festival-of-biologics/2020-speakers.stm
I wonder if there will be modi1 trial data coming in by then